Sakaguchi Isao, Motohara Takeshi, Saito Fumitaka, Takaishi Kiyomi, Fukumatsu Yukitoshi, Tohya Toshimitsu, Shibata Saburo, Mimori Hiroyuki, Tashiro Hironori, Katabuchi Hidetaka
Department of Obstetrics and Gynecology, Kumamoto University Faculty of Life Sciences, Kumamoto, Japan.
Department of Obstetrics and Gynecology, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan.
J Gynecol Oncol. 2015 Jul;26(3):193-200. doi: 10.3802/jgo.2015.26.3.193. Epub 2015 Feb 17.
The aim of this study was to determine the efficacy and toxicity of oral administration of tegafur-uracil (UFT) at a high dose, 600 mg/day, based on the tegafur dose, against uterine cervical cancer.
This study consisted of a retrospective analysis. From April 1986 to March 1997, 309 patients with uterine cervical cancer were registered. Oral UFT was administered to 162 patients for maintenance therapy after an initial treatment (the UFT group). The other 147 patients were not treated with UFT (the control group). The survival rate was calculated for both groups and statistically analyzed using the log-rank test. Adverse events were compared between the UFT and control groups.
In the UFT group, 103 patients (63.6%) received UFT for ≥90 days. The drug dose was 600 mg/day for 137 patients (84.6%) and 300 to 400 mg/day for the remainder. The overall survival rate was significantly higher in the UFT group than in the control group (p<0.05). The prognosis was particularly favorable in stage III cases, in cases of squamous cell carcinoma, and in cases that were treated by radiotherapy. The most frequent side effects were nausea/vomiting (12.2%), appetite loss (10.1%), and leukopenia/neutropenia (5.8%).
High-dose oral UFT maintenance treatment prolonged the disease-free survival and overall survival of patients with uterine cervical cancer, particularly of those with advanced disease.
本研究旨在确定基于替加氟剂量为600mg/天的口服替加氟-尿嘧啶（UFT）对子宫颈癌的疗效和毒性。
本研究为回顾性分析。1986年4月至1997年3月，登记了309例子宫颈癌患者。162例患者在初始治疗后接受口服UFT进行维持治疗（UFT组）。另外147例患者未接受UFT治疗（对照组）。计算两组的生存率，并使用对数秩检验进行统计学分析。比较UFT组和对照组的不良事件。
在UFT组中，103例患者（63.6%）接受UFT治疗≥90天。137例患者（84.6%）的药物剂量为600mg/天，其余患者为300至400mg/天。UFT组的总生存率显著高于对照组（p<0.05）。III期病例、鳞状细胞癌病例以及接受放射治疗的病例预后尤其良好。最常见的副作用是恶心/呕吐（12.2%）、食欲减退（10.1%）和白细胞减少/中性粒细胞减少（5.8%）。
高剂量口服UFT维持治疗可延长子宫颈癌患者的无病生存期和总生存期，尤其是晚期疾病患者。
